| LZIOX | VDVIX | LZIOX / VDVIX | |
| Total Expense Ratio | 1.08 | 0.16 | 675% |
| Annual Report Gross Expense Ratio | 1.08 | 0.16 | 675% |
| Fund Existence | 30 years | 13 years | - |
| Gain YTD | 8.844 | 16.722 | 53% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 2500 | 0 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 1.27B | 324B | 0% |
| Annual Yield % from dividends | 1.72 | 2.37 | 73% |
| Returns for 1 year | 4.56 | 21.95 | 21% |
| Returns for 3 years | 39.92 | 63.48 | 63% |
| Returns for 5 years | 8.23 | 41.64 | 20% |
| Returns for 10 years | 45.15 | 110.42 | 41% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| DNEMX | 21.88 | 0.23 | +1.06% |
| Dunham Emerging Markets Stock N | |||
| GSUKX | 25.80 | 0.26 | +1.02% |
| Goldman Sachs International Eq Inc R6 | |||
| TRPIX | 57.64 | 0.43 | +0.75% |
| T. Rowe Price Value I | |||
| TSVAX | 23.33 | 0.13 | +0.56% |
| PGIM Quant Solutions Small-Cap Val A | |||
| FRBRX | 212.75 | -0.45 | -0.21% |
| Franklin Biotechnology Discovery R6 | |||